Table 1 Characteristics of the study sample (n = 161)
Male sex, % | 97 (60.2%) |
Age, years | 37.4 ± 13.4 |
Duration of diabetes, years | 17.7 ± 10.6 |
Insulin pump, % | 65 (40.6%) |
Hypertension, % | 30 (18.9%) |
Dyslipidemia, % | 65 (41.1%) |
Body mass index, kg/m2 | 24.8 ± 4.0 |
Systolic pressure, mmHg | 126.0 ± 15.5 |
Diastolic pressure, mmHg | 72.6 ± 10.0 |
Total cholesterol, mg/dL | 164.5 ± 34.6 |
LDL cholesterol, mg/dL | 93.6 ± 26.9 |
HDL cholesterol, mg/dL | 57.0 ± 14.5 |
Triglycerides, mg/dL | 78.1 ± 38.0 |
Education | |
Less than hight school graduate, % | 1 (1.5%) |
High school graduate, % | 1 (1.5%) |
Some college education, % | 23 (35.4%) |
College degree or higher, % | 40 (61.5%) |
Other antidiabetic drugs | |
SGLT2 inhibitors, % | 18 (11.2%) |
Metformin, % | 17 (10.6%) |
GLP-1 analogue, % | 5 (3.1%) |
DPP-4 inhibitors, % | 1 (0.6%) |
Thiazolidinedione, % | 0 (0%) |
Sulfonylureas, % | 0 (0%) |
Any complication | 52 (32.3%) |
Microvascular complication | 49 (30.4%) |
Retinopathy, % | 39 (24.2%) |
Nephropathy, % | 18 (11.2%) |
Peripheric neuropathy, % | 4 (2.5%) |
Macrovascular complication | 13 (8.1%) |
Ischemic coronary disease, % | 4 (2.5%) |
Cerebrovascular disease, % | 5 (3.1%) |
Peripheral arterial disease, % | 6 (3.7%) |
Heart Failure | 0 (0%) |